Triptolide inhibited Toll-like receptor 4 (TLR4)/NF-κB signaling to enhance pancreatic-cancer-cell-line sensitivity to gemcitabine, which resulted in decreased tumor cell proliferation, viability and xenograft tumor volume (181). The gene discussed is NFKB1; the disease is neoplasm.